| Gene Symbol | C1Q |
| Full Name | c1q |
| Protein Type | Signaling Protein |
| Target Class | Signaling Protein |
| Function | Complement cascade inhibitor or antibody-mediated neutralization |
| Mechanism of Action | Complement cascade inhibitor or antibody-mediated neutralization |
| Primary Expression | Primarily expressed in myeloid cells (monocytes, macrophages, microglia); astrocytic expression detected in disease states |
| Subcellular Localization | synapses, dystrophic neurites, extracellular protein aggregates, and vascular interfaces. These features make C1QA a hig |
| Druggability | Low (0.36) |
| Clinical Stage | Approved |
| Molecular Weight | 26 kDa |
| Pathways | Chaperone, Complement, Differentiation, Endocytosis, Epigenetic |
| UniProt ID | P02745 |
| NCBI Gene ID | 712 |
| Ensembl ID | ENSG00000173372 |
| GeneCards | C1Q |
| Human Protein Atlas | C1Q |
| Associated Diseases | A1 Astrocytes, A1 Reactive Astrocytes, AD, AGING, ALI, AML |
| Known Drugs/Compounds | RAPAMYCIN, Beta-Amyloid Oligomers, β-amyloid Oligomers, rapamycin, β-Amyloid Oligomers, LPS |
| Interactions | C3, C1QA, C1QC, RAB11, RAB5, CNTNAP4 |
| SciDEX Target | View Target Profile (4 clinical trials) |
| KG Connections | 1529 knowledge graph edges |
| Databases | GeneCardsHPASTRING |